Literature DB >> 17257594

Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.

Leslie Bailey1, Asa Gylfe, Charlotta Sundin, Sandra Muschiol, Mikael Elofsson, Peter Nordström, Birgitta Henriques-Normark, Raimond Lugert, Anders Waldenström, Hans Wolf-Watz, Sven Bergström.   

Abstract

Intracellular parasitism by Chlamydiales is a complex process involving transmission of metabolically inactive particles that differentiate, replicate, and re-differentiate within the host cell. A type three secretion system (T3SS) has been implicated in this process. We have here identified small molecules of a chemical class of acylated hydrazones of salicylaldehydes that specifically blocks the T3SS of Chlamydia. These compounds also affect the developmental cycle showing that the T3SS has a pivotal role in the pathogenesis of Chlamydia. Our results suggest a previously unexplored avenue for development of novel anti-chlamydial drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17257594     DOI: 10.1016/j.febslet.2007.01.013

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  48 in total

Review 1.  Computational prediction of type III and IV secreted effectors in gram-negative bacteria.

Authors:  Jason E McDermott; Abigail Corrigan; Elena Peterson; Christopher Oehmen; George Niemann; Eric D Cambronne; Danna Sharp; Joshua N Adkins; Ram Samudrala; Fred Heffron
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  A multi-pronged search for a common structural motif in the secretion signal of Salmonella enterica serovar Typhimurium type III effector proteins.

Authors:  Garry W Buchko; George Niemann; Erin S Baker; Mikhail E Belov; Richard D Smith; Fred Heffron; Joshua N Adkins; Jason E McDermott
Journal:  Mol Biosyst       Date:  2010-09-29

Review 3.  The biology and future prospects of antivirulence therapies.

Authors:  Lynette Cegelski; Garland R Marshall; Gary R Eldridge; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

Review 4.  New frontiers in type III secretion biology: the Chlamydia perspective.

Authors:  K E Mueller; G V Plano; K A Fields
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

Review 5.  Anti-virulence strategies to combat bacteria-mediated disease.

Authors:  David A Rasko; Vanessa Sperandio
Journal:  Nat Rev Drug Discov       Date:  2010-01-18       Impact factor: 84.694

6.  Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7.

Authors:  Jai J Tree; Dai Wang; Carol McInally; Arvind Mahajan; Abigail Layton; Irene Houghton; Mikael Elofsson; Mark P Stevens; David L Gally; Andrew J Roe
Journal:  Infect Immun       Date:  2009-07-27       Impact factor: 3.441

7.  Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts.

Authors:  Laura Mannonen; Eveliina Markkula; Mirja Puolakkainen
Journal:  Med Microbiol Immunol       Date:  2011-01-30       Impact factor: 3.402

8.  Novel Role for PilNO in Type IV Pilus Retraction Revealed by Alignment Subcomplex Mutations.

Authors:  Tiffany L Leighton; Neha Dayalani; Liliana M Sampaleanu; P Lynne Howell; Lori L Burrows
Journal:  J Bacteriol       Date:  2015-04-27       Impact factor: 3.490

9.  Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

Authors:  Anatoly Slepenkin; Per-Anders Enquist; Ulrik Hägglund; Luis M de la Maza; Mikael Elofsson; Ellena M Peterson
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

10.  Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.

Authors:  Jianfang Li; Chao Lv; Weiyang Sun; Zhenyu Li; Xiaowei Han; Yaoyao Li; Yuemao Shen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.